Status Update on the National Cardiovascular Prevention Guidelines - JNC 8, ATP 4, and Obesity 2
|
|
- Cordelia Marshall
- 5 years ago
- Views:
Transcription
1 TABLE OF CONTENTS Status Update on the National Cardiovascular Prevention Guidelines 1 Drosperinone-Containing Oral Contraceptives and Venous Thromboembolism Risk 1-4 P&T Committee Formulary Action 5 Status Update on the National Cardiovascular Prevention Guidelines - JNC 8, ATP 4, and Obesity 2 The National Heart, Lung, and Blood Institute (NHLBI) has been in the process of updating national hyperlipidemia, hypertension, and obesity guidelines for many years. The process has been painstakingly slow with many clinicians currently expressing concern over the reasons given for holding back the new guidelines and the impact these delays may be having on patient care. The last set of NHLBI guidelines for these disease states were issued in: 2001, with a 2004 update, for the Adult Treatment Panel Detection, Evaluation, and Treatment of High Blood Cholesterol (ATP III) guidelines; 2003 for the Seventh Edition of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines; 1998 for the Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. At the recent 2011 American Heart Association (AHA) meeting, long-awaited key details from the new guidelines were to be presented; however, attendees at the spotlight session were merely treated to an explanation of the delayed process as well as an overview of critical questions being addressed for all 3 guidelines. The main factor behind the slow down in guideline development was the release of a March 2011 Institute of Medicine report entitled Clinical Practice Guidelines We Can Trust. This report contained 8 standards for developing rigorous, trustworthy clinical practice guidelines. These standards were incorporated into the national cardiovascular prevention guidelines development process thereby delaying completion, with the end result hopefully being an improvement in the overall quality of the guidelines. In addition, these new guidelines incorporate a vast amount of clinical data. For the JNC 8 guidelines alone, the expert committee performed a literature review back to Across all 3 guidelines, approximately 39,000 papers were screened, graded, and abstracted. At the AHA meeting, expert panel members presented critical questions that will be used as the basis for recommendations within each guideline. These are presented in Table 1. During the AHA presentation, it was noted that all 3 guidelines should be released sometime in 2012, potentially within the first 6 months. In addition, the NHLBI announced that an expert panel will be working towards development of an integrated guideline that incorporates information from the hyperlipidemia, hypertension, and obesity reports. This integrated guideline may potentially be completed in 2 years. Drosperinone-Containing Oral Contraceptives and Venous Thromboembolism Risk Drospirenone, a unique fourth generation progestogen, has been approved by the Food and Drug Administration (FDA) for the prevention of pregnancy in combination with ethinyl estradiol (EE) since May Drospirenone, an analogue of spironolactone, displays antimineralocorticoid activity due to increasing sodium and water excretion, and antiandrogenic activity by blocking androgen receptors in skin. Its proposed benefits include reducing problems with weight gain, acne, hirsutism, as well as having a more favorable effect on the lipid profile when compared with older progestogens. Yaz and Yasmin, drospirenone-containing oral contraceptives (OCs), have consistently been among the top 200 drugs in the country. Shortly after approval, reports of venous thromboembolism (VTE) began to surface among users of OCs containing drospirenone. As of the middle of 2002, 40 cases of VTE had been reported in European women receiving OCs containing drospirenone and 30 mcg of EE. 1
2 Table 1. Critical Questions to be Addressed by National Cardiovascular Prevention Guidelines. Guideline Critical Questions Comments ATP 4 JNC 8 Obesity 2 1. What evidence supports LDL-C goals for secondary prevention? 2. What evidence supports LDL-C goals for primary prevention? 3. What is the impact of the major cholesterol medications on efficacy and safety? 1. Does initiating antihypertensive drug therapy at specific blood pressure thresholds improve outcomes? When should treatment be initiated? 2. Does treatment with antihypertensive drug therapy to a specified blood pressure goal lead to improvements in outcomes? How low should you go? 3. Do various antihypertensive drugs or drug classes differ in comparative benefits and harms for specific outcomes? How do you get there? 1. What are the benefits of weight loss? 2. What are the risks of being overweight? 3. What is the efficacy of different diet strategies? 4. What is the role of a comprehensive lifestyle intervention (diet plus exercise plus behavioral therapy) in achieving and maintaining weight loss? 5. What are the benefits and risks of various bariatric procedures? The impact of diet/exercise is being evaluated in a separate lifestyle working group. Randomized controlled trials and high-quallity meta-analyses were considered in this guideline. These guidelines only considered evidence from randomized controlled trials. Pharmacologic interventions will not be included in this guideline due to a lack of sufficient evidence. Several studies have been conducted to evaluate and quantify the risk of VTE with drospirenone-containing OCs. No increase in VTE risk with drosperinone-containing OCs as compared to other OCs was observed in the results of 2 cohort studies published in one involving women 10 to 59 years of age from a U.S. health insurer database (United Healthcare) and the other involving women with mean ages of 25 to 27 years from 7 European countries (the European Active Surveillance [EURAS] study). In contrast, in 2009, results from a cohort study conducted in women age 15 to 49 years using various types of OCs from 4 national Danish registries between 1995 and 2005, and a case-control study conducted in the Netherlands (women 18 to 50 years of age) found a 1.5- to 2-fold higher VTE risk in drospirenone recipients compared to women receiving levonorgestrel. Based on results from the 4 studies mentioned above, FDA alerted the public about the potential increased risk of VTE in women using drospirenone-containing OCs on May 31, At the time of this initial safety announcement, FDA stated that it was continuing to review the data and would communicate additional information when available. The safety announcement was updated on September 26, 2011 coinciding with publication of 2 additional cohort studies, which are described in the next sections. Recent Literature 2011 U.S. Data The first study was conducted in the U.S. to assess the risk of non-fatal idiopathic VTE in women receiving drospirenone-containing OCs compared with those receiving levonorgestrel-containing OCs. Participant data were collected from claims paid by managed care plans in the PharMetrics database, a database containing prescription drug claims, medical diagnoses, procedures, and demographic information on 55 million people. The investigator included data for women 15 to 44 years of age who received either drospirenone or levonorgestrelcontaining OCs after January 1, 2002 (current users). Cases were defined as women receiving the study OCs who had medical history in the database for at least 6 months before their first-time claim for deep vein thrombosis (DVT) or pulmonary embolism (PE) who subsequently received anticoagulation therapy. Women who had documentation of any VTE risk factors within 90 days before the index date were excluded from the study in order to focus on women with idiopathic VTE. Controls were matched to each case by age (4:1). A nested case-control design was used to determine the impact of confounding variables such as age, duration of OC use, obesity, and emergency department visits on the results of the study. Conditional logistic 2
3 regression was used to analyze the matched case-control data. Controlled variables were age and date of diagnosis. Data were analyzed to estimate the incidence rate and 95% confidence intervals (CIs). The study population consisted of 186 cases and 681 controls. When compared with control, cases had a higher percentage of obesity (13% vs. 6%) and emergency department visits (9% vs. 3%). Women using drospirenone were younger (higher percentage in <30 years of age group), had a shorter duration of OC use, and were more likely to have a history of menstrual disorders. Among cases with idiopathic VTE, 121 (65%) were using drospirenonecontaining OCs, and 65 (35%) were taking a levonorgestrelcontaining agent. Among the control group, 313 (46%) were receiving drospirenone compared to 368 (54%) using levonorgestrel-containing OCs. The unadjusted matched odd ratio (OR) for VTE with drospirenone-containing OCs compared to those containing levonorgestrel was 2.3 (95% CI 1.6 to 3.2). Among women younger than 30 years of age, those who used drospirenone-containing OCs had a higher risk of VTE (OR 3.7, 95% CI 2.0 to 6.9) than younger women using levonorgestrel-containing OCs. The incidence rates of VTE in women receiving drospirenone and levonorgestrelcontaining OCs were 30.8 (95% CI 25.6 to 36.8) and 12.5 (95% CI 9.61 to 15.9) per 100,000 woman years, respectively. The incidence of VTE increased with increasing age for both types of OCs. The authors concluded that risk of VTE in women receiving drospirenone-containing OCs was about double the risk of their counterparts receiving a levonorgestrel-containing OC. UK Data The second nested case-control study was conducted in the UK to examine the risk of non-fatal idiopathic VTE in current users of OCs containing drospirenone compared to those using levonorgestrel. Overall study design was similar to the U.S. study. Women from the UK General Practice Research Database 15 to 44 years of age who received either drospirenone or levonorgestrel-containing OCs between May 1, 2002 and September 30, 2009 were included to the study. Included cases were those who had a medical history recorded in the database for at least 1 year and were diagnosed with either DVT or PE with subsequent anticoagulation therapy in the absence of history or risk factors for VTE. Controls were matched to each case (up to 4 per case) by year of birth (within 2 years), number of years of recorded date, and general practice. Conditional logistic regression was used to compute OR and 95% CI in this case-control analysis. Potential confounding factors were body mass index (BMI), history of varicose veins, smoking status, and antidepressant use. The study population included 61 cases and 215 controls. Seventeen (28%) cases and 26 (12%) controls were users of drospirenone-containing OCs (unadjusted OR 3.2, 95% CI 1.5 to 7). The mean age of cases and controls was similar (32.2 vs years of age). Cases had a higher proportion of women with BMI 25 than controls (61% vs. 31%); OR adjusted for BMI was 3.3 (95% CI 1.4 to 7.6). Further adjustment for confounding factors (BMI, history of varicose veins, smoking status, and antidepressant use) showed results similar to the unadjusted analysis (OR 3.1, 95% CI 1.3 to 7.5). The investigators also found that differences in age (<35 years, and 35 years), duration of OC use, and history of OC use before the current episode (no previous use vs. at least 1 previous episode of use) did not significantly affect the excess risk of VTE in users of drospirenone-containing OCs. The unadjusted incidence rates of VTE for current users of drospirenone and levonorgestrel-containing OCs were 23 (95% CI 13.4 to 36.9) and 9.1 (95% CI 6.6 to 12.2) per 100,000 woman years, respectively. The incidence rate ratio adjusted for age was 2.7 (95% CI 1.5 to 4.7). The authors concluded that drospirenone-containing OCs cause a higher risk of VTE compared to levonorgestrel-containing OCs. FDA Safety Announcement September 26, 2011 and Literature Update Although the results of the 2 most recently published studies showed an increased risk of VTE in women using OCs containing drospirenone compared with levonorgestrel, the FDA stated that further review of the data is warranted. The agency has scheduled a joint meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee for December 8, 2011 to discuss the risk of VTE with drospirenone-containing OCs. In the meantime, the FDA has suggested the following for healthcare professionals ( Drugs/DrugSafety/ucm htm): Consider the risks and benefits of OCs containing drospirenone prior to prescribing with consideration for the individual patient s risk for developing VTE. Some risk factors for VTE include smoking, obesity, and family history of VTE. Counsel patients about the current information on the risk of VTE with OCs containing drospirenone compared with levonorgestrel. The studies assessing risk of VTE have only evaluated the OC containing drospirenone and 30 mcg EE, so these results might not apply to other drospirenone-containing products with a lower dose of EE. Report adverse events involving OCs to FDA Med- Watch ( medwatch-online.htm). In addition to the results of the recently published studies, the safety announcement also mentioned preliminary data from an FDA-funded epidemiologic study that found a 1.5 times increased risk of VTE in users of OCs containing drospirenone compared to other OCs. Recently, the final report of the study has been published on the FDA s website ( UCM pdf). 3
4 The study was conducted to assess the risk of VTE in women 10 to 55 years of age using newer combined hormonal contraceptives including the drospirenone and EE OC, the norelgestromin (third generation) and EE transdermal patch, and the etonogestrel (third generation) and estradiol vaginal ring compared with those using standard OCs with low estrogen levels from 4 U.S. health plan databases between January 1, 2001 and December 31, The standard comparator OCs included: 0.10 mg levonorgestrel + 20 mcg EE 0.15 mg levonorgestrel + 30 mcg EE 1 mg norethindrone acetate + 20 mcg EE mg norgestimate + 35 mcg EE There were 835,826 women with 898,251 person-years of combined hormonal contraceptive use included in the study. The final cohort contained 189,210 person-years of drospirenone use, 67,865 person-years of norelgestromin use, 23,910 person-years of etonogestrel use, and 617,265 person-years of the standard combined OCs (comparator) use. Key results showed a significantly increased risk of VTE in users of drospirenone and EE tablet, norelgestromin and EE transdermal patch, and etonogestrel and estradiol vaginal ring with adjusted relative risk (RR) of VTE of 1.74 (95% CI 1.42 to 2.14), 1.55 (95% CI 1.17 to 2.07), and 1.56 (95% CI 1.02 to 2.37), respectively compared to standard therapy. The analysis was restricted to new users, and only the drospirenone-containing regimen was associated with a higher risk of VTE (RR 1.77, 95% CI 1.33 to 2.35) and arterial thrombotic events (RR 2.01, 95% CI 1.06 to 3.81). Another analysis focused on duration of exposure. Increased risk of VTE was found with drospirenone use for less than 3 months (RR 1.93, 95% CI 1.24 to 3.00) and 6 to 12 months (RR 2.80, 95% CI 1.48 to 5.29) relative to comparators. The norelgestromin patch had a higher risk of VTE with more than 12 months of exposure (RR 3.05, 95% CI 1.23 to 7.53). The conclusion of this FDA analysis was that drospirenone, norelgestromin transdermal patch, and etonogestrel vaginal ring were associated with a higher risk of VTE compared with the standard, low-dose, estrogen-containing OCs. Following the FDA safety announcement, another study was published in the British Medical Journal online October 25, This study was an extension of the Danish study published in 2009, and the objective was to assess the risk of VTE in users of combined OCs according to progestogen type and estrogen dose. Participants were women 15 to 49 years of age without history of or risk factors for VTE from Danish registries. Data were analyzed by multiple Poisson regression, and RR was adjusted for age, calendar year, level of education, and duration of OC use; smoking data were not available. Never-users and former-users, collectively defined as non-users, of all types of hormonal contraception methods were used as the reference group for RR analysis. There were 1,296,120 women and 4307 first-time VTE events included in the analysis, and a total of 2847 (67%) of VTE events were confirmed. The incidence rate of VTE in non-users of hormonal contraception was 3.7 per 10,000 woman years. All users of combined OCs had a significantly increased risk of VTE, while users of progestogen-only contraceptives did not compared to non-users. The highest adjusted RR of VTE was seen in users of the OCs containing norethisterone and 50 µg EE (5.66, 95% CI 3.12 to 10.3), and the lowest adjusted RR of VTE was seen in users of OCs containing norethisterone and 30 to 40 mcg EE (1.57, 95% CI 0.84 to 2.92). The adjusted RR of VTE in users of OCs with levonorgestrel and 30 mcg EE and users of OCP with drospirenone and 30 µg EE were 2.19 (95% CI 1.74 to 2.75) and 4.47 (95% CI 3.91 to 5.11), respectively. The adjusted RR in drospirenone users was a bit higher (4.84, 95% CI 3.19 to 7.33) when using the lower estrogen dose (20 mcg) formulation. In the analysis of the confirmed VTE cases, adjusted rate ratio of VTE risk of drospirenone users relative to levonorgestrel users was 2.12 (95% CI 1.68 to 2.66). Similar rate ratios of VTE risk, relative to levonorgestrel users, were also seen in users of OCP containing desogestrel (2.20, 95% CI 1.74 to 2.77), and gestodene (2.07, 95% CI 1.70 to 2.52). Further adjustment for duration of OC use did not change the increased risk of VTE in drospirenone users, but decreased the risk in gestodene users. The investigators also conducted sensitivity analyses, but no substantial changes were observed. The authors concluded that the risk of VTE among users of OCs containing drospirenone, desogestrel, or gestodene was at least twice that compared to users of OCs containing levonorgestrel. Summary Recent literature consistently supports an increased risk for VTE among woman taking drospirenone-containing OCs compared to women using levonorgestrel-containing products. This risk has been shown even in women with shortterm use of drospirenone (<3 months). A joint meeting of 2 FDA advisory committees will occur in early December 2011 to discuss the risks and benefits of drospirenone-containing OCs. In the meantime, healthcare providers are encouraged to carefully assess risk factors for VTE prior to prescribing OCs, notably drospirenone-containing regimens. Although the fourth generation progestin may offer some benefits in terms of its antimineralocorticoid activity, it is unclear if the potential benefits outweigh the established risk for VTE. 4
5 P&T Formulary Committee Action* *The P&T Committee actions are effective when formulary changes have been implemented in the Cerner System. Additions - Losartan - Atorvastatin - formulary use restriction removed Deletions - Valsartan - Telmisartan - Simavastatin - Drotrecogin alfa - Mebendazole Authors: Michael Gabay PharmD, JD, BCPS Amy Lodolce PharmD, BCPS Suputat Chumnumwat PharmD candidate Editor: Michael Gabay PharmD, JD, BCPS 5
Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
open access Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the and databases Yana Vinogradova, Carol Coupland, Julia Hippisley-Cox Division of
More informationRisk of venous thromboembolism in users of non-oral contraceptives Statement from the Faculty of Sexual and Reproductive Healthcare
Risk of venous thromboembolism in users of non-oral contraceptives Statement from the Faculty of Sexual and Reproductive Healthcare New data A paper published in May 2012 in the British Medical Journal
More informationRESEARCH. Susan S Jick, director and senior epidemiologist Rohini K Hernandez, epidemiologist
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United
More informationCombined oral contraceptives and risk of venous thromboembolism: nested case control studies using the QResearch and the CPRD databases
Combined oral contraceptives and risk of venous thromboembolism: nested case control studies using the QResearch and the CPRD databases Yana Vinogradova, Carol Coupland, Julia Hippisley-Cox Web appendix:
More informationQUESTIONS AND ANSWERS ON COMBINED HORMONAL CONTRACEPTIVES: LATEST INFORMATION FOR WOMEN
QUESTIONS AND ANSWERS ON COMBINED HORMONAL CONTRACEPTIVES: LATEST INFORMATION FOR WOMEN Why is new information being made available now? A recent Europe wide review looked at the benefits and risks of
More information1. Ng M et a l. Global, regional, and national prevalence of overweight and obesity in children and adults during : A systematic analysis
1 2 3 1. Ng M et a l. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980 2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet
More informationElements for a Public Summary. VI.2.1 Overview of Disease Epidemiology
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Etonogestrel/ethinylestradiol vaginal delivery system is a vaginal ring form of birth control used to prevent unplanned pregnancy
More informationElements for a Public Summary. Overview of Disease Epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of Disease Epidemiology Etonogestrel/ethinylestradiol vaginal delivery system is a vaginal ring form of birth control used to prevent unplanned pregnancy
More informationCURRENT HORMONAL CONTRACEPTION - LIMITATIONS
CURRENT HORMONAL CONTRACEPTION - LIMITATIONS Oral Contraceptives - Features MERITS Up to 99.9% efficacy if used correctly and consistently Reversible method rapid return of fertility Offer non-contraceptive
More informationHormonal contraception and risk of venous thromboembolism: national follow-up study
Hormonal contraception and risk of venous thromboembolism: national follow-up study Øjvind Lidegaard, professor, 1 Ellen Løkkegaard, consultant, 2 Anne Louise Svendsen, statistician, 3 Carsten Agger, data
More informationOral contraceptives Epidemiological aspects Øjvind Lidegaard
Oral contraceptives Epidemiological aspects Øjvind Lidegaard Professor Gynaecological Clinic 4232 Rigshospitalet Copenhagen University OC: Epidemiological aspects OC use OC and thrombosis - venous thromboembolism
More informationHormonal Treatment of Acne and Hirsutism. Julie C Harper MD
Hormonal Treatment of Acne and Hirsutism Julie C Harper MD none Conflict of Interest Androgen blockade Decrease androgen production by the gonads or adrenal gland Decrease circulating free testosterone
More informationHRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College
HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now
More informationOral contraception in Denmark
A C TA Obstetricia et Gynecologica AOGS MAIN RESEARCH ARTICLE Oral contraception in Denmark 1998 2010 NADIA M. WILSON 1, MAJA LAURSEN 2 & ØJVIND LIDEGAARD 1 1 Gynecological Clinic, Rigshospitalet University
More informationHormonal contraception and thrombosis. An update
Hormonal contraception and thrombosis. An update Øjvind Lidegaard Clinical Professor in Obstetrics & Gynaecology Barcelona, Spain, 21.2.2015 Department of Gynaecology, Rigshospitalet Faculty of Health
More informationTrudy Bush Lecture: Using Progestins in Clinical Practice. Progestins in Clinical Practice: Outline. NAMS Definitions. FDA Approved Oral Progestins
1 Women's Health 2015: The 23rd Annual Congress FRIDAY, April 17, 2015 Trudy Bush Lecture: Using Progestins in Clinical Practice Commercial Disclosure: I am a consultant on litigation relating to the Mirena
More informationContraccezione e tromboembolismo venoso
Contraccezione e tromboembolismo venoso Ida Martinelli Centro Emofilia e Trombosi Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico - Milano XXVII Congresso Nazionale FCSA Milano, 20-22.10.2016
More informationDianette (cyproterone acetate 2mg/ethinylestradiol 35 mcg): Strengthening of warnings, new contraindications, and updated indication
Dianette (cyproterone acetate 2mg/ethinylestradiol 35 mcg): Strengthening of warnings, new contraindications, and updated indication Dear Healthcare Professional, In agreement with the European Medicines
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationAppendix A Materials Considered by Dr. Shelley Tischkau In addition to the materials specifically referenced in my report, the other materials I have considered are: Literature Editorial: Sex Hormone Binding
More informationEarly release, published at on November 7, Subject to revision.
CMAJ Early release, published at www.cmaj.ca on November 7, 2011. Subject to revision. Research Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based
More informationBreast Cancer Risk in Patients Using Hormonal Contraception
Breast Cancer Risk in Patients Using Hormonal Contraception Bradley L. Smith, Pharm.D. Smith.bradley1@mayo.edu Pharmacy Ground Rounds Mayo Clinic Rochester April 3 rd, 2018 2017 MFMER slide-1 Presentation
More informationOverview of reports of thromboembolic adverse drug reactions associated with cyproterone/ethinylestradiol
Overview of reports of thromboembolic adverse drug reactions associated with cyproterone/ethinylestradiol Introduction The European Medicines Agency s Pharmacovigilance Risk Assessment Committee (PRAC)
More informationUse of hormonal therapy in acne
Acne Guidelines Use of hormonal therapy in acne Julie C Harper MD Conflict of Interest Disclosure Speaker/Advisor Allergan Bayer Galderma Valeant Investigator Bayer Our task: What is the effectiveness
More informationWhat s New in Adolescent Contraception?
What s New in Adolescent Contraception? Abby Furukawa, MD Legacy Medical Group Portland Obstetrics and Gynecology April 29, 2017 Objectives Provide an update on contraception options for the adolescent
More informationAddressing Inadequate Information on Important Health Factors in Pharmacoepidemiology Studies relying on Healthcare Databases
Addressing Inadequate Information on Important Health Factors in Pharmacoepidemiology Studies relying on Healthcare Databases Efe Eworuke, Ph.D. Simone P. Pinheiro, Sc.D. M.Sc. Division of Epidemiology
More informationRisk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis
CMAJ Research Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis Steven T. Bird PharmD MS, Abraham G. Hartzema PhD PharmD, James M. Brophy
More informationExpanding Access to Birth Control: Will Women Get the Care They Need?
Expanding Access to Birth Control: Will Women Get the Care They Need? Target Audience: Pharmacists ACPE#: 0202-0000-18-045-L01-P Activity Type: Application-based Target Audience: ACPE#: Activity Type:
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationAmerican Journal of Internal Medicine
American Journal of Internal Medicine 2016; 4(3): 49-59 http://www.sciencepublishinggroup.com/j/ajim doi: 10.11648/j.ajim.20160403.12 ISSN: 2330-4316 (Print); ISSN: 2330-4324 (Online) The Effect of Dose-Reduced
More informationTime Topic Speaker Abbreviation
1. Programme Sunday, 4 th November 2018 Time Topic Speaker Abbreviation 08:00 Welcome, distribution materials 08:30 Overview of the Medical Eligibility Criteria (2015), and the Selected Practices Recommendations
More informationInstructions how to use the ESC teach the teachers course and self-learning tool
Instructions how to use the ESC teach the teachers course and self-learning tool Welcome to the ESC advanced learning tool To improve and facilitate knowledge and use of contraception, abortion, sexually
More informationPicking the Perfect Pill How to Effectively Choose an Oral Contraceptive
Focus on CME at Queen s University Picking the Perfect Pill How to Effectively Choose an Oral Contraceptive By Susan Chamberlain, MD, FRCSC There are over 20 oral contraceptive (OC) preparations on the
More informationTable I. Examples of Hormone and Tapering Regimens
Table I. Examples of Hormone and Tapering Regimens Severe AUB Heavy bleeding (soaking through 2 maxi pads an hour, 2 hours in a row) History of heavy menses Hemodynamically un (tachycardia, hypotensive,
More informationThrombotic Stroke and Myocardial Infarction with Hormonal Contraception
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Thrombotic Stroke and Myocardial Infarction with Hormonal Contraception Øjvind Lidegaard, Dr. Med. Sci., Ellen Løkkegaard, Ph.D.,
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationHormonal contraception: NHS Tayside Formulary, pharmacological content and other characteristics
Hormonal contraception: NHS Tayside Formulary, pharmacological content and other characteristics Advice from the Tayside Sexual & Reproductive Health Service (TSRHS) (Last update: 10/2017) Combined hormonal
More informationHaemostasis, thrombosis risk and hormone replacement therapy
Haemostasis, thrombosis risk and hormone replacement therapy Serge Motte Brussels 13.05.17 - MY TALK TODAY The coagulation cascade and its regulation Effects of hormone replacement therapy on haemostasis
More informationBMI and Contraception: What s the Evidence?
BMI and Contraception: What s the Evidence? Kathryn M. Curtis, PhD Division of Reproductive Health Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion
More informationUPDATE: Women s Health Issues
UPDATE: Women s Health Issues Renee B. Alexis, MD, MBA, MPH, FACOG Associate Professor Department of OBGYN Kiran C. Patel College of Osteopathic Medicine Disclosure of Conflicts of Interest I have no financial
More informationCausal Inference Framework for Considering the Cardiovascular Risks Associated with Ortho Evra
Causal Inference Framework for Considering the Cardiovascular Risks Associated with Ortho Evra B. Burt Gerstman June 2008 This brief document addresses the question Does Ortho Evra cause more cardiovascular
More informationContraception: Common Problems Faced in Office Practice. Jane S. Sillman, MD Brigham and Women s Hospital
Contraception: Common Problems Faced in Office Practice Jane S. Sillman, MD Brigham and Women s Hospital Disclosures I have no conflicts of interest Contraception: Common Problems How to discuss contraception
More informationClinical Challenges in Contraception. Disclosures. Objectives Pharmacists 4/3/2018
Clinical Challenges in Contraception Kathleen Besinque, PharmD Sarah McBane, PharmD Disclosures Kathleen Besinque has nothing to disclose Sarah McBane has nothing to disclose Objectives Pharmacists Compare
More informationContraception for Obese Women RENEE E. MESTAD, MD, MSCI ACOG DISTRICT II UPSTATE MEETING APRIL 29, 2016
Contraception for Obese Women RENEE E. MESTAD, MD, MSCI ACOG DISTRICT II UPSTATE MEETING APRIL 29, 2016 Disclosure I am a Nexplanon trainer for Merck. Objectives Understand how obesity may affect pharmacokinetics
More informationObjectives. Outline. Media Worthy Trials? Making Sense out of the Sensationalism 8/30/2012
Media Worthy Trials? Making Sense out of the Sensationalism Lara K. Ellinger, PharmD, BCPS Clinical Assistant Professor, Drug Information Group University of Illinois at Chicago I have no actual or potential
More information2/4/2011. What is your specialty? A. Family practice B. Internal medicine and subs C. OB/GYN D. Peds E. Surgery and subs
Steve P. Buchanan D.O. FACOOG(Dist.) TOMA Mid Winter February 11, 2011 Dallas,TX Associate Professor OB/GYN UNTHSC/TCOM 1987- present Executive Vice President, American College of Osteopathic Obstetricians
More informationContraception. Yolanda Evans MD MPH Assistant Professor of Pediatrics Division of Adolescent Medicine
Contraception Yolanda Evans MD MPH Assistant Professor of Pediatrics Division of Adolescent Medicine Disclosures No financial relationships to disclose I have no commercial, financial, research ties to
More informationInstructions how to use the ESC teach the teachers course and self-learning tool
Instructions how to use the ESC teach the teachers course and self-learning tool Welcome to the ESC advanced learning tool To improve and facilitate knowledge and use of contraception, abortion, sexually
More informationConsensus Statement on the Use of Oral Contraceptive Pills in Polycystic Ovarian Syndrome Women in India
Consensus Statement Consensus Statement on the Use of Oral Contraceptive Pills in Polycystic Ovarian Syndrome Women in India Duru Shah 1,2, Madhuri Patil 3,4,5, On behalf of the National PCOS Working Group
More informationAnne H. Calhoun, MD, FAHS Professor of Anesthesiology Professor of Psychiatry
Combined Hormonal Contraceptives & Migraine with Aura Anne H. Calhoun, MD, FAHS Professor of Anesthesiology Professor of Psychiatry University of North Carolina Partner/Co-Founder Carolina Headache Institute
More informationPRESCRIBING HORMONAL CONTRACEPTIVES TO WOMEN WITH MIGRAINE (CON) Disclosures. Objectives/Discussion Points 6/2/2017
PRESCRIBING HORMONAL CONTRACEPTIVES TO WOMEN WITH MIGRAINE (CON) Gretchen E. Tietjen, MD Department of Neurology University of Toledo Disclosures Advisory Boards: Eli Lilly, Dr. Reddy s Common Stock: J&J,
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES TRANSMITTED BY FACSIMILE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Nancy Konnerth Associate Director, Advertising and Labeling Drug Regulatory
More informationPeggy Piascik, PhD Associate Professor, Pharmacy Practice and Science
Peggy Piascik, PhD Associate Professor, Pharmacy Practice and Science Department, UK College of Pharmacy Describe extended cycle oral contraceptive characteristics including dosing regimen, indications,
More informationBirth Control in Patients with Congenital Heart Disease
Birth Control in Patients with Congenital Heart Disease Arwa Saidi MB. BCh. MEd. FACC University of Florida Departments of Pediatrics and Internal Medicine Gainesville, FL There are an increasing number
More informationHormonal contraception and acne
Hormonal contraception and acne Øjvind Lidegaard Dansk Dermatologisk Selskab 15.1.2014 Gynaecological Clinic, Rigshospitalet University of Copenhagen OC generations according to oestrogen dose and progestogen
More informationVENOUS THROMBOEMBOLISM: DURATION OF TREATMENT
VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE
More informationMenopausal Hormone Therapy & Haemostasis
Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen
More informationHyperandrogenism and polycystic ovary syndrome are clear casual factors (trends) which result in hirsuitism and acne.
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Indication: Treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism,
More informationPage 1 of 46. DROSPIRENONE, ETHINYL ESTRADIOL and LEVOMEFOLATE CALCIUM Tablets and LEVOMEFOLATE CALCIUM Tablets, for oral use
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets and Levomefolate Calcium Tablets
More informationAnnex II Scientific conclusions and grounds for variation to the terms of the marketing authorisations subject to conditions
Annex II Scientific conclusions and grounds for variation to the terms of the marketing authorisations subject to conditions Page 24 Scientific conclusions and grounds for the variation to the terms of
More informationLearning objectives. Some fun facts. Presenter Disclosure Information. Become familiar with the newest contraceptive options available
8:45 9:30 am Advances and Options in Female Contraception SPEAKER Pelin Batur, MD, FACP, NCMP, CCD Presenter Disclosure Information The following relationships exist related to this presentation: Pelin
More informationThrombosis and Women s Health Risk factors, contraceptive pill, HRT and your doctor
Thrombosis and Women s Health Risk factors, contraceptive pill, HRT and your doctor Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service
More informationRESEARCH. Katrina Wilcox Hagberg, 1 Hozefa A Divan, 2 Rebecca Persson, 1 J Curtis Nickel, 3 Susan S Jick 1. open access
open access Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
More informationIMPACT OF ORAL CONTRACEPTIVES AND SMOKING ON ARTERIAL AND DEEP VENOUS THROMBOSIS:
Article DOI: 10.2478/v10133-010-0054-y MB IMPACT OF ORAL CONTRACEPTIVES AND SMOKING ON ARTERIAL AND DEEP VENOUS THROMBOSIS: А RETROSPECTIVE case-control STUDY V. Tzankova 1, V. Petrov 2 and N. Danchev
More informationRESEARCH INTRODUCTION ABSTRACT
Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database Lianne Parkin, senior
More informationInfections of the genito-urinary system and sexually transmitted diseases Please refer to the Treatment of infections in Primary Care section
Genito-urinary System Infections of the genito-urinary system and sexual transmitted diseases - Please refer to the Treatment of infections in Primary Care section Combined Hormonal Contraceptives Combined
More informationThe biology of menstrually related. Ovulation Suppression of Premenstrual Symptoms Using Oral Contraceptives REPORTS. Patricia J.
REPORTS Ovulation Suppression of Premenstrual Symptoms Using Oral Contraceptives Patricia J. Sulak, MD Abstract Managing premenstrual symptoms at the most fundamental level necessitates careful consideration
More informationCase 3:15-cv PLR-HBG Document Filed 01/20/17 Page 1 of 5 PageID #: 1412
6 Case 3:15-cv-00137-PLR-HBG Document 33-36 Filed 01/20/17 Page 1 of 5 PageID #: 1412 588084TAW0010.1177/2042098615588084Therapeutic Advances in Drug SafetyEtminan research-article2015 Therapeutic Advances
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationHormone Replacement Therapy (HRT) Benefits & Risks - The Facts
Hormone Replacement Therapy (HRT) Benefits & Risks - The Facts HRT is a prescription only treatment that replaces some of the lost oestrogen and progesterone hormones which occur during menopause. It can
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/188/20915 holds various files of this Leiden University dissertation. Author: Flinterman, Linda Elisabeth Title: Risk factors for a first and recurrent venous
More informationInternational Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: , ISSN(Online): Vol.9, No.11, pp , 2016
International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: 0974-4304, ISSN(Online): 2455-9563 Vol.9, No.11, pp 246-251, 2016 The Effects of Yasmin on the Histology and Histochemistry of Liver
More informationDeep Vein Thrombosis
Deep Vein Thrombosis from NHS (UK) guidelines Introduction Deep vein thrombosis (DVT) is a blood clot in one of the deep veins in the body. Blood clots that develop in a vein are also known as venous thrombosis.
More informationWhat You Should Know
1 New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know The American Society
More informationDifferences in the use of combined oral contraceptives amongst women with and without acne
Human Reproduction Vol.18, No.3 pp. 515±521, 2003 DOI: 10.1093/humrep/deg090 Differences in the use of combined oral contraceptives amongst women with and without acne H.E.Seaman 1, C.S.de Vries and R.D.T.Farmer
More informationA Practitioner s Toolkit for the Management of the Menopause
Medicine, Nursing and Health Sciences A Practitioner s Toolkit for the Management of the Menopause Developed by the Women s Health Research Program School of Public Health and Preventive Medicine Monash
More informationVI.2. ELEMENTS FOR A PUBLIC SUMMARY
VI.2. ELEMENTS FOR A PUBLIC SUMMARY VI.2.1 Overview of Disease Epidemiology COCs (Combined Oral Contraceptives) containing DRSP-EE (Drospirenone- Ethinylestradiol) are indicated for the prevention of pregnancy
More informationAll medications are a double-edged sword with risks
Menopause: The Journal of The North American Menopause Society Vol. 14, No. 5, pp. 1/14 DOI: 10.1097/gme.0b013e31802e8508 * 2007 by The North American Menopause Society REVIEW ARTICLE Postmenopausal hormone
More informationVenous Thrombo-Embolism (VTE)
Venous Thrombo-Embolism (VTE) Information for service users and carers RDaSH leading the way with care Older People s Mental Health Services Reducing risk of unwanted blood clots whilst in hospital About
More informationCancer and blood clots
n The Leeds Teaching Hospitals NHS Trust Cancer and blood clots What you should know whilst you are in source isolation Information for thyroid patients Please read this leaflet carefully. It will give
More informationHormonal contraception and venous thrombosis An up-date
Hormonal contraception and venous thrombosis An up-date Øjvind Lidegaard Rigshospitalet 5. marts 2012 Gynaecological Clinic, Rigshospitalet University of Copenhagen OC generations according to oestrogen
More informationEpidemiologia e clinica del tromboembolismo venoso. Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione
Epidemiologia e clinica del tromboembolismo venoso Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione Thrombophilia may present clinically as one or more of several thrombotic manifestations
More informationCLINICAL PEARLS IN CONTRACEPTION
CLINICAL PEARLS IN CONTRACEPTION Laura Borgelt, PharmD, FCCP, BCPS Associate Professor University of Colorado Denver PharmCon, Inc. is accredited by the Accreditation Council for Pharmacy Education as
More informationEstrogens and progestogens
Estrogens and progestogens Estradiol and Progesterone hormones produced by the gonads are necessary for: conception embryonic maturation development of primary and secondary sexual characteristics at puberty.
More informationOverview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Acne vulgaris (or simply acne) is a common human skin disease, characterized by areas of skin with seborrhea (scaly red skin),
More informationAbnormal Uterine Bleeding Case Studies
Case Study 1 Abnormal Uterine Bleeding Case Studies Abigail, a 24 year old female, presents to your office complaining that her menstrual cycles have become a problem. They are now lasting 6 7 days instead
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationJan/Feb Vol 15 No 1. Immune globulins and the risk for thrombotic events
Jan/Feb 2014 Vol 15 No 1 RxPress TABLE OF CONTENTS Immune globulins and the risk for thrombotic events 1-2 Upcoming changes to the pregnancy labeling of drugs 2-3 Key features of the new hypertension treatment
More informationThe Journal of Headache and Pain
Sacco et al. The Journal of Headache and Pain (2017) 18:108 DOI 10.1186/s10194-017-0815-1 The Journal of Headache and Pain CONSENSUS ARTICLE Hormonal contraceptives and risk of ischemic stroke in women
More informationDiscontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database
open access Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database Yana Vinogradova, 1 Carol Coupland, 1 Peter Brindle, 2,3 Julia Hippisley-Cox
More informationLearning objectives. Some fun facts. Presenter Disclosure Information. Discuss the newest contraceptive options available
2:15 3pm Advances and Options in Female Contraception SPEAKER Pelin Batur, MD, FACP, NCMP, CCD Presenter Disclosure Information The following relationships exist related to this presentation: Pelin Batur,
More informationMay 10, 2016 Q & Business Update
May 10, 2016 Q1 2016 Thank Financial you Results & Business Update Q1 2016 Financial Results Prepared Remarks Q1 Update Tom Hughes, Ph.D., Chief Executive Officer Clinical Update Dennis Kim, M.D., Chief
More informationDate of preparation: September 2014 L.GB d
Date of preparation: September 2014 L.GB.12.2013.4666d This medicine is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk
More informationDeciding whether or not to use Hormone Therapy (HT) is a big decision and should be
Deciding whether or not to use Hormone Therapy (HT) is a big decision and should be made with input from your healthcare provider. After the decision has been made to take HT, many women don t realize
More informationSummary A LOOK AT ELAGOLIX FOR ENDOMETRIOSIS JULY 2018
JULY 2018 WHAT IS ENDOMETRIOSIS? Endometriosis is a chronic gynecological condition with symptoms that include painful menstrual periods, nonmenstrual pelvic pain, and pain during intercourse, as well
More informationTransgender Medicine beyond the guidelines.
Transgender Medicine beyond the guidelines. Rachel Hopkins, MD Assistant Professor of Medicine SUNY Upstate Medical University Division of Endocrinology and Metabolism Overview Definitions and history
More informationAppendix: Reference Table of HT Brand Names
Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug
More informationRivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Rivaroxaban is a non-vitamin K antagonist
More informationPrescribing spironolactone for acne. Julie C Harper MD
Prescribing spironolactone for acne Julie C Harper MD Conflict of Interest Disclosure none Spironolactone FDA-approval in 1960 Current FDA-approved indications: Primary hyperaldosteronism Edematous conditions
More information2
1 2 3 1. Usinger KM et al. Intrauterine contraception continuation in adolescents and young women: a systematic review. J Pediatr Adolesc Gynecol 2016; 29: 659 67. 2. Kost K et al. Estimates of contraceptive
More information